Abstract:Patients with primary refractory acute myeloid leukemia (AML) have a dismal long-term prognosis. Elucidating the resistance mechanisms to induction chemotherapy could help identify strategies to improve AML patient outcomes. Herein, we retrospectively analyzed the multi-omics data of more than 1,500 AML cases and found that patients with spliceosome mutations had a higher risk of developing refractory disease. RNA splicing analysis revealed that the mis-spliced genes in refractory patients converged on translation-associated pathways, promoted mainly by U2AF1 mutations. Integrative analyses of binding and splicing in AML cell lines substantiated that the splicing perturbations of mRNA translation genes originated from both the loss and gain of mutant U2AF1 binding. In particular, the U2AF1-S34F and U2AF1-Q157R mutants orchestrated the inclusion of exon 11 (encoding a premature termination codon) in the eukaryotic translation initiation factor 4A2 (EIF4A2). This aberrant inclusion led to reduced eIF4A2 protein expression via nonsense-mediated mRNA decay. Consequently, U2AF1 mutations caused a net decrease in global mRNA translation that induced the integrated stress response (ISR) in AML cells, which was confirmed by single-cell RNA-seq. The induction of ISR enhanced the ability of AML cells to respond and adapt to stress, contributing to chemoresistance. A pharmacologic inhibitor of ISR, ISRIB, sensitized U2AF1 mutant cells to chemotherapy. These findings highlight a resistance mechanism by which U2AF1 mutations drive chemoresistance and provide a therapeutic approach for AML through targeting the ISR pathway.

Supplementary Methods and Figure S1-S12 from Mutant U2AF1-Induced Mis-Splicing of Mrna Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia

Supplementary Table S1-S20 from Mutant U2AF1-Induced Mis-Splicing of mRNA Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia

Mutant U2AF1-induced mis-splicing of mRNA translation genes confers resistance to chemotherapy in acute myeloid leukemia

Supplementary Data from an Alternatively Spliced P62 Isoform Confers Resistance to Chemotherapy in Breast Cancer

Supplementary Figures from A PolH Transcript with a Short 3′UTR Enhances PolH Expression and Mediates Cisplatin Resistance

Targeted Inhibition Of Stat/Tet1 Axis As A Therapeutic Strategy For Acute Myeloid Leukemia (Vol 8, 2017)

Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes

Supplementary Figure S4 from Combination Therapy Targeting Ribosome Biogenesis and Mrna Translation Synergistically Extends Survival in MYC-Driven Lymphoma

Supplementary Figure S3 from Combination Therapy Targeting Ribosome Biogenesis and Mrna Translation Synergistically Extends Survival in MYC-Driven Lymphoma

Multi-omics profiling of U2AF1 mutants dissects pathogenic mechanisms affecting RNA granules in myeloid malignancies

Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing

The Biological and Clinical Consequences of RNA Splicing Factor U2AF1 Mutation in Myeloid Malignancies

Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1

Supplementary Methods, Figures 1-3 from Synergistic Antitumor Activity of Gemcitabine and ABT-737 in Vitro and in Vivo Through Disrupting the Interaction of USP9X and Mcl-1

Supplementary Figures 1-5 from Mechanisms of &Lt;i>nt5c2</i>-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia

Supplemental Figure 4 Dose-dependent Inhibition from Acquired <i>met</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Supplementary Methods and Materials, Figure Legend from ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM

Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance